{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:17:43Z","timestamp":1778771863481,"version":"3.51.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T00:00:00Z","timestamp":1358294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0053795","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T22:21:01Z","timestamp":1358374861000},"page":"e53795","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression"],"prefix":"10.1371","volume":"8","author":[{"given":"Che-Ming","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ling","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Chi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen-Jei","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-An","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng-Fu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajni","family":"Josson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland W. K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shian-Ying","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"L Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1046\/j.1532-5415.2003.51367.x","article-title":"Metastatic prostate cancer: complications and treatment","volume":"51","author":"CT McMurtry","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000474402","article-title":"Quality of life of patients with advanced and metastatic prostatic carcinoma","volume":"24","author":"H Villavicencio","year":"1993","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/clinchem\/41.5.644","article-title":"Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation","volume":"41","author":"WB Coleman","year":"1995","journal-title":"Clin Chem"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"DR Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"CN Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1158\/0008-5472.CAN-05-1162","article-title":"Resistance to paclitaxel is proportional to cellular total antioxidant capacity","volume":"65","author":"B Ramanathan","year":"2005","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1128\/MCB.24.12.5172-5183.2004","article-title":"Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor","volume":"24","author":"OM Fischer","year":"2004","journal-title":"Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0006-291X(02)00302-9","article-title":"A secreted form of human ADAM9 has an alpha-secretase activity for APP","volume":"293","author":"N Hotoda","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1093\/emboj\/17.24.7260","article-title":"A metalloprotease-disintegrin, MDC9\/meltrin-gamma\/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor","volume":"17","author":"Y Izumi","year":"1998","journal-title":"Embo J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20041133","article-title":"The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins","volume":"385","author":"RM Mahimkar","year":"2005","journal-title":"Biochem J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.23974","article-title":"UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines","volume":"124","author":"B Singh","year":"2009","journal-title":"Int J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1158\/0008-5472.CAN-05-4375","article-title":"Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells","volume":"66","author":"SY Sung","year":"2006","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.eururo.2007.11.034","article-title":"ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer","volume":"54","author":"FR Fritzsche","year":"2008","journal-title":"Eur Urol"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Pen CC, Liu CM, Lin CC, Lin CC, Hsieh TF, <etal>et al<\/etal>.. (2012) Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer. Chin J Physiol 55: E-pub ahead of print; DOI: 10.4077\/CJP.2012.BAA075.","DOI":"10.4077\/CJP.2012.BAA075"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pros.21237","article-title":"Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy","volume":"71","author":"S Josson","year":"2011","journal-title":"Prostate"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1158\/0008-5472.CAN-08-2492","article-title":"Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis","volume":"68","author":"SY Sung","year":"2008","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Ormerod MG (2000) Flow Cytometry: a practical approach; Ormerod MG, editor: Oxford University Press.","DOI":"10.1093\/oso\/9780199638253.001.0001"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pros.20565","article-title":"Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells","volume":"67","author":"K Shigemura","year":"2007","journal-title":"Prostate"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ijc.26089","article-title":"Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer","volume":"130","author":"K Vanderlaag","year":"2012","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"IF Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"DP Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"JS de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"HI Scher","year":"2010","journal-title":"Lancet"},{"key":"ref25","first-page":"21","article-title":"The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy","volume":"18","author":"MR Smith","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"K Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"PW Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"EJ Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"PW Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"MR Smith","year":"2012","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2004.03.047","article-title":"Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel","volume":"214","author":"DX Cao","year":"2004","journal-title":"Cancer Lett"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.onc.1210681","article-title":"Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells","volume":"27","author":"T Mizumachi","year":"2008","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"23386","DOI":"10.1074\/jbc.M109.034090","article-title":"Shedding of collagen XVII\/BP180 in skin depends on both ADAM10 and ADAM9","volume":"284","author":"CW Franzke","year":"2009","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1158\/0008-5472.CAN-09-4231","article-title":"Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration","volume":"70","author":"JL Fry","year":"2010","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1074\/jbc.M111.321190","article-title":"Lung Cancer-derived Galectin-1 Enhances Tumorigenic Potentiation of Tumor-associated Dendritic Cells by Expressing Heparin-binding EGF-like Growth Factor","volume":"287","author":"PL Kuo","year":"2012","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"D Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref37","first-page":"237","article-title":"The role of mitochondria in bee venom-induced apoptosis in human breast cancer MCF7 cells","volume":"22","author":"SW Ip","year":"2008","journal-title":"In Vivo"},{"key":"ref38","first-page":"918","article-title":"Reg IV, a differentially expressed gene in colorectal adenoma","volume":"116","author":"Y Zhang","year":"2003","journal-title":"Chin Med J (Engl)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1349-7006.2006.00297.x","article-title":"Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4","volume":"97","author":"A Takehara","year":"2006","journal-title":"Cancer Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.humpath.2009.06.001","article-title":"Reg IV expression and clinicopathologic features of gallbladder carcinoma","volume":"40","author":"H Tamura","year":"2009","journal-title":"Hum Pathol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ijc.10788","article-title":"Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas","volume":"103","author":"S Violette","year":"2003","journal-title":"Int J Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jso.22021","article-title":"REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma","volume":"105","author":"JH Moon","year":"2012","journal-title":"J Surg Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-04-0356","article-title":"Reg IV: a promising marker of hormone refractory metastatic prostate cancer","volume":"11","author":"Z Gu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref44","first-page":"95","article-title":"Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker","volume":"21","author":"T Hayashi","year":"2009","journal-title":"Oncol Rep"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1349-7006.2008.00846.x","article-title":"Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer","volume":"99","author":"S Ohara","year":"2008","journal-title":"Cancer Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2184.2008.00577.x","article-title":"Reg IV enhances peritoneal metastasis in gastric carcinomas","volume":"42","author":"H Kuniyasu","year":"2009","journal-title":"Cell Prolif"},{"key":"ref47","first-page":"689","article-title":"REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells","volume":"36","author":"L Rafa","year":"2010","journal-title":"Int J Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/labinvest.3700507","article-title":"Expression of the REG IV gene in ulcerative colitis","volume":"87","author":"A Nanakin","year":"2007","journal-title":"Lab Invest"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0053795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T20:00:34Z","timestamp":1714852834000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0053795"}},"subtitle":[],"editor":[{"given":"Irina U.","family":"Agoulnik","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0053795","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,16]]}}}